How Biogen outbid a rival for $7.3B Reata buy

This Week

Aug 18, 2023

Another round of layoffs hits BMS, with 100-plus people impacted after earnings miss 


Thermo Fisher lays off 200-plus at clinical-stage cell and gene therapy factory in Florida 


FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death 


How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B 


FDA puts 2seventy CAR-T trial on hold in wake of patient death 


'The Top Line': Trends at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage 

 

Featured

Another round of layoffs hits BMS, with 100-plus people impacted after earnings miss

Bristol Myers Squibb has laid off more than 100 employees amid a reconfiguration of expenses that follows disappointing earnings results.  
11-14
Sep
Philadelphia, PA
 

Top Stories

Thermo Fisher lays off 200-plus at clinical-stage cell and gene therapy factory in Florida

As layoffs continue to roil the biotech industry, bigger drugmakers and manufacturers like Bristol Myers Squibb and Emergent BioSolutions haven’t been immune. Now, Thermo Fisher Scientific is among the latest to plot hundreds of job cuts.

FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death

Gilead Sciences' $225 million bet on Arcellx’s CAR-T cell therapy is back in play after the FDA lifted a clinical hold instigated in the wake of a patient death.

How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B

Biogen’s $7.3 billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month. But it turns out Biogen wasn’t the only drugmaker jockeying for the Texas-based rare disease outfit, a new securities filing shows.

FDA puts 2seventy CAR-T trial on hold in wake of patient death

The FDA has put an early-phase trial of 2seventy bio’s CD33-targeted CAR-T cell therapy on hold in the wake of a patient death.

'The Top Line': Trends at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage

This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage

AstraZeneca hit with FDA warning letter over 'misleading' Breztri efficacy claims

AstraZeneca’s promotion of Breztri Aerosphere has landed it in hot water with the FDA. The agency says an AstraZeneca sales aid made “misleading” claims about the effect of the inhaler on all-cause mortality, prompting it to send a warning letter to CEO Pascal Soriot.

Italian billionaires behind Ferrari, Juventus drop $2.8B to become Philips' largest single shareholder

Though rebuked by shareholders in a vote earlier this year that kept its executives potentially liable for any legal issues related to its recent recall-related troubles, Philips has gotten a major confidence boost from a new investor.

Gracell drops 3 CAR-T programs in hopes of speeding more advanced assets to the finish line

Gracell Biotechnologies is shaving down its CAR-T pipeline, throwing several programs out the window in an effort to speed its most advanced programs to the finish line. 

Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2

Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far. Meanwhile, only six of the industry’s top 20 firms experienced revenue decreases, with Pfizer's sales dropping a whopping 54%.

Sequel plots next generation of menstrual care with FDA clearance of new tampon design

It’s not often that a sequel is better than the original, but one startup developing a new approach to period products is banking on it.

Pfizer faces whistleblower lawsuit from former compliance manager who says he flagged possible fraud in China

Frank Han, Pfizer's former director of global compliance analytics, has filed a civil complaint against the drugmaker. Han claims he was terminated for identifying potential issues relating to the Foreign Corrupt Practices Act.
 
Fierce podcasts

Don’t miss an episode

'The Top Line': Cannes Lions, top paid CEOs, and a drug shortage

This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage

 

Resources

Whitepaper

Challenges of Cell Line Development: Stable Transfection

Unravel the intricacies of Cell Line Development in biotherapeutics production with our latest eBook chapter.
Whitepaper

Plan for success with your process liquid and buffer preparation

Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity.

Video

Decipher the Blueprint for Your Clinical Development Transformation

Learn how to turn patient-focused innovations into life-changing treatments.
Whitepaper

Key Drivers of Sales Force Strategy in Oncology

In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today.
Research

Reduce chemical lead times with just-in-time delivery

Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery.
Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.
 
 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events